Nektar Therapeutics (NKTR) Long-Term Investments (2011 - 2026)

Nektar Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $163.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 2001.24% year-over-year to $163.0 million; the TTM figure through Mar 2026 stood at $163.0 million (up 2001.24% YoY), while the FY2024 annual figure was $12.2 million, down 52.69% from the prior year.
• Long-Term Investments was $163.0 million for Q1 2026 at Nektar Therapeutics, up from $5.4 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $163.0 million in Q1 2026 to a low of $4.5 million in Q3 2024.
• Historically, Long-Term Investments has averaged $32.1 million across 5 years, with a median of $15.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Long-Term Investments slumped 84.45% in 2022, then jumped 2001.24% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $8.9 million in 2022, then surged by 189.26% to $25.8 million in 2023, then sank by 52.69% to $12.2 million in 2024, then plunged by 56.04% to $5.4 million in 2025, then soared by 2934.69% to $163.0 million in 2026.
• The last three Long-Term Investments figures came in at $163.0 million (Q1 2026), $5.4 million (Q2 2025), and $7.8 million (Q1 2025), per Business Quant data.